Videos

Hanneke Schuitemaker, PhD, explains the challenges faced when creating a vaccine for HIV.

Magda Opsomer, MD, shares the results of the Phase 3 EMERALD trial for darunavir.

Jessica Justman, MD, explains how decision makers can use the Population-based HIV Impact Assessment Project data.

Viviane Boaventura, MD, MsC, PhD, discusses ongoing research related to auditory complications due to congenital Zika syndrome.

William D. O’Riordan, MD, FACEP, explains what makes iclaprim a unique antibiotic.

David Huang, PhD, MD, explains what the next steps are for iclaprim, an antibiotic developed to treat patients with acute bacterial skin and skin structure infections.

Alan Gross, PharmD, shares the drawbacks of some of the current prediction tools used for pneumonia.

Joergen Richt, DVM, PhD, discusses which animal models are being used to study Zika virus.

Alex Rinehart, PhD, explains if cabotegravir interacts with any other medications.

Jessica Justman, MD, reveals the latest results of the Population-based HIV Impact Assessment Project (2017).

Viviane Boaventura, MD, MsC, PhD, shares how past research has demonstrated that adults can experience Zika-associated hearing loss.

Silvio Pitlik, MD, visiting scientist, Weizmann Institute of Science, Israel, explains how the first Lyme disease patients were misdiagnosed.

Daniel Pilch, PhD, explains how the health care system must change in order to battle antibiotic resistance.

Alan Gross, PharmD, shares how an early diagnosis of multidrug-resistant pneumonia can work towards improving patient outcomes.

Joergen Richt, DVM, PhD, discusses the transmission cycle of Zika virus.

Milena McLaughlin, PharmD, MSc, explains how officials test if a drug is counterfeit or active.

Meghan Jeffres, PharmD, shares what should be considered when considering the incorporation of penicillin skin testing into a health care facility.

Silvia Munoz-Price, MD, PhD, explains different elements that should be incorporated into training programs for hospital epidemiologists.

Alex Rinehart, PhD, identifies the target population for cabotegravir.

Jessica Justman, MD, shares why the Population-based HIV Impact Assessment Project is so important.

Daniel Pilch, PhD, explains which patients would not make good candidates for MRSA prodrug TXA709.

Edmond LaVoie, PhD, shares different approaches that can be used to forestall the development of antibiotic resistance.

Alan Gross, PharmD, BCPS-AQID, shares how the Society of Infectious Diseases Pharmacists is working to improve antibiotic stewardship programs in long-term care facilities.

Joergen Richt, DVM, PhD, discusses animals that have proven susceptible to Zika virus replication after experimental infection.

Silvia Munoz-Price, MD, PhD, shares a few issues that hospital epidemiologists currently face.

Julian Hurdle, PhD, explains research focused on validating FabK as an essential enzyme to be used as a narrow-spectrum drug target against Clostridium difficile.

Jason Pogue, PharmD, BCPS-ID, explains the clinical significance of his research team’s findings regarding the use of ceftolozane-tazobactam to treat Pseudomonas infections.

Alex Rinehart, PhD, explains how cabotegravir is a gender-neutral pre-exposure prophylaxis medication.